Concepedia

Michael S. Hofman

MS

174

Publications

17.2K

Citations

64

H-Index

2003

Active since

Affiliations

Peter MacCallum Cancer Centre(Current)

The University of Melbourne

Monash University

St Vincent's Hospital Sydney

The University of Sydney

Michael S. Hofman is an author at Peter MacCallum Cancer Centre specializing in medicine, oncology, and radiation oncology.

ORCID

Top concepts

Publications per year

2003–2025

174

Publications

174

Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study

Michael S. Hofman, Nathan Lawrentschuk, Roslyn J. Francis et al. · The Lancet · 2020 · 1.8K citations

, , +12

[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study

Michael S. Hofman, John Violet, Rodney J. Hicks et al. · The Lancet Oncology · 2018 · 1.1K citations

[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial

Michael S. Hofman, Louise Emmett, Shahneen Sandhu et al. · The Lancet · 2021 · 1K citations

, , +7

Somatostatin Receptor Imaging with<sup>68</sup>Ga DOTATATE PET/CT: Clinical Utility, Normal Patterns, Pearls, and Pitfalls in Interpretation

Michael S. Hofman, Eddie Lau, Rodney J. Hicks · Radiographics · 2015 · 537 citations

Dosimetry of <sup>177</sup>Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: Correlations Between Pretherapeutic Imaging and Whole-Body Tumor Dosimetry with Treatment Outcomes

John Violet, Price Jackson, Justin Ferdinandus et al. · Journal of Nuclear Medicine · 2018 · 454 citations · Full text

Rows per page

1–5 of 174